Keros Therapeutics (NASDAQ:KROS) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research note published on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating on the stock.

Several other equities research analysts have also commented on KROS. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target for the company. Bank of America reduced their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Trading Up 2.0 %

Shares of KROS stock opened at $60.76 on Thursday. Keros Therapeutics has a 12-month low of $27.02 and a 12-month high of $73.00. The stock has a market capitalization of $2.28 billion, a P/E ratio of -11.84 and a beta of 1.23. The firm’s 50 day moving average is $54.91 and its 200 day moving average is $51.83.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the prior year, the business posted ($1.27) EPS. As a group, equities analysts predict that Keros Therapeutics will post -4.88 earnings per share for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the 3rd quarter valued at about $89,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter worth about $128,000. Finally, Bayesian Capital Management LP bought a new stake in Keros Therapeutics during the first quarter worth approximately $267,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.